News from Asia

The Bulletin

The Times

.

Fri Oct 30

BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100

Written by The Bulletin

Ad hoc announcement pursuant to Art. 53 LR

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).

Read more: BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100

More Articles ...

What the Label on a Pallet Tells a Warehouse Before Anyone Opens It

Executive Recruitment for Education Leadership: What Schools Should Consider

Practical Guide to Roller Shutters for Safer, More Comfortable Homes

Why the Advertised Rate on a Bonus Saver Account Isn't What Most Savers Actually Earn

The Essential Bathroom Renovation Supplies Checklist Before You Start

Pull Up Stands: A Convenient Display Option for Events and Promotions

How Mining Hose Selection Can Improve Material Transfer Systems

Electric Sliding Door: What to Consider Before Choosing One

What Is Included in a Professional Roof Repair Service on the Gold Coast?

The Unglamorous Baby Buys That Save Australian Parents the Most Time

Cryptocurrency Trading in 2026_ Why Regulated Education Is the New Standard

How Mining Hose Routing Can Influence Wear and Transfer Efficiency

hacklink zlibrary zlibrary z-library Metin2 pvp Serverler kralbet jojobet casibom casibom jojobet justintv taraftarium meritking hacklink panel marsbahis vsf watches jojobet uk casinos not on gamstop GamStop deneme bonusu veren yeni siteler